International Journal of Radiation Oncology * Biology * Physics
Volume 57, Issue 5 , Pages 1254-1259 , 1 December 2003

Hypofractionated conformal radiotherapy in carcinoma of the prostate: five-year outcome analysis

Presented in 2002 to the American Society for Therapeutic Radiology and Oncology (Abstract 1052).

  • Jacqueline E Livsey, F.R.C.R.

      Affiliations

    • Department of Clinical Oncology, Christie Hospital NHS Trust, Manchester, England, United Kingdom
    • ,
  • Richard A Cowan, F.R.C.R.

      Affiliations

    • Department of Clinical Oncology, Christie Hospital NHS Trust, Manchester, England, United Kingdom
    • ,
  • James P Wylie, F.R.C.R.

      Affiliations

    • Department of Clinical Oncology, Christie Hospital NHS Trust, Manchester, England, United Kingdom
    • ,
  • Ric Swindell, M.Sc.

      Affiliations

    • Department of Medical Statistics, Christie Hospital NHS Trust, Manchester, England, United Kingdom
    • ,
  • Graham Read, F.R.C.R.

      Affiliations

    • Department of Clinical Oncology, Royal Preston Hospital, Preston, England, United Kingdom
    • ,
  • Vincent S Khoo, F.R.A.C.R.

      Affiliations

    • Academic Department of Radiation Oncology, Christie Hospital NHS Trust, Manchester, England, United Kingdom
    • ,
  • John P Logue, F.R.C.R.

      Affiliations

    • Department of Clinical Oncology, Christie Hospital NHS Trust, Manchester, England, United Kingdom
    • Corresponding Author InformationReprint requests to: J. P. Logue, Christie Hospital NHS Trust, Wilmslow Road, Withington, Manchester, UK M20 4BX. Tel: 44-161 4463000; Fax: 44-161 4468111

Received 7 February 2003 ,Revised 2 May 2003 ,Accepted 9 June 2003.

References 

  1. Brenner DJ, Hall EJ. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys. 1999;43:1095–1101
  2. Fowler J, Chappell R, Ritter M. Is α/β for prostate tumors really low?. Int J Radiat Oncol Biol Phys. 2001;50(4):1021–1031
  3. Rew DA, Wilson GD. Cell production rates in human tissues and tumours and their significance. Part II (Clinical data). Eur J Surg Oncol. 2000;26:405–417
  4. Logue JP, Cowan RA, Hendry JH. Hypofractionation for prostate cancer. Int J Radiat Oncol Biol Phys. 2001;49:1522–1523
  5. Kupelian PA, Reddy CA, Klein EA, et al.  Short-course intensity-modulated radiotherapy (70Gy at 2.5Gy per fraction) for localized prostate cancer (Preliminary results on late toxicity and quality of life). Int J Radiat Oncol Biol Phys. 2001;51:988–993
  6. Catton CN, Chung P, Haycocks T, et al.  Hypofractionated intensity modulated radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2002;54(2S):188
  7. American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus Statement. Guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus Statement. Int J Radiat Oncol Biol Phys 1997;37:1035–1041
  8. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31:1341–1346
  9. ICRU Report No. International Commission on Radiation Units and Measurements: Prescribing, recording and reporting photon beam therapy. Washington, DC: International Commission on Radiation Units and Measurements; 1993
  10. Read G, Pointon RCS. Retrospective study of radiotherapy in early carcinoma of the prostate. Br J Urol. 1989;63:191–195
  11. Zelefsky MJ, Leibel SA, Gaudin PB, et al.  Dose escalation with three-dimensional conformal radiotherapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys. 1998;41:491–500
  12. Lyons JA, Kupelian PA, Mohan DS, et al.  Importance of high radiation doses (72Gy or greater) in the treatment of stage T1–3 adenocarcinoma of the prostate. Urology. 2000;55:85–90
  13. Hanks GE, Hanlon AL, Schultheis TE, et al.  Dose escalation with 3D conformal treatment (Five year outcomes treatment optimization, and future directions). Int J Radiat Oncol Biol Phys. 1998;41:501–510
  14. Pollack A, Zagars GK, Smith LG, et al.  Preliminary results of a randomised radiotherapy dose-escalation study comparing 70Gy with 78Gy for prostate cancer. J Clin Oncol. 2000;18:3904–3911
  15. Zelefsky MJ, Fuks Z, Happersett L, et al.  Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer. Radiother Oncol. 2000;55:241–249
  16. Horwitz EM, Hanlon AL, Pinover WH, et al.  Defining the optimal radiation dose with three-dimensional conformal radiation therapy for patients with non metastatic prostate carcinoma by using recursive partitioning techniques. Cancer. 2001;92:1281–1287
  17. Pollack A, Smith LG, von Eschenbach AC. External beam radiotherapy dose response characteristics of 1127 men with prostate cancer treated in the PSA era. Int J Radiat Oncol Biol Phys. 2000;48:507–512
  18. Patterson R. The treatment of malignant disease by radiotherapy. Frome and London: Butler and Tanner; 1963. p. 25–46
  19. Dearnaley DP, Khoo VS, Norman AR, et al.  Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer (A randomised trial). Lancet. 1999;353(9149):267–272
  20. Storey MR, Pollack A, Zagars G, et al.  Complications from radiotherapy dose escalation in prostate cancer (Preliminary results of a randomised trial). Int J Radiat Oncol Biol Phys. 2000;48:635–642
  21. Ryu JK, Winter K, Michalski J, et al. Interim report of toxicity from 3D conformal radiation therapy (3D-CRT) for prostate cancer on 3DOG/RTOG 9406, level III (79.2 Gy). Int J Radiat Oncol Biol Phys 2002;54:1036–1046
  22. Litwin MS, Hays RD, Fink A, et al. The UCLA Prostate Cancer Index. Development, reliability and validity of a health related quality of life measure. Med Care 1998;36:1002–1012
  23. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). Conceptual framework and item selection. Med Care. 1992;30:473–483
  24. Davidson SE, Burns M, Routledge J, et al.  Short report (A morbidity scoring system for clinical oncology practice: Questionnaires produced from the LENT SOMA scoring system). Clin Oncol. 2002;14:68–69
  25. Livsey JE, Routledge J, Burns M, et al.  Scoring of treatment related late effects in prostate cancer. Radiother Oncol. 2002;65:109–121

☆ No acknowledgments or disclaimers.

PII: S0360-3016(03)00752-1

doi: 10.1016/S0360-3016(03)00752-1

International Journal of Radiation Oncology * Biology * Physics
Volume 57, Issue 5 , Pages 1254-1259 , 1 December 2003

Article Tools

* Image Usage & Resolution